A tale of two neurology companies: evolution of Lundbeck and Biogen

A pair of neurology companies are in the spotlight on the latest edition of the BioCentury This Week podcast. BioCentury’s editors assess how  H. Lundbeck A/S (CSE:LUN) has evolved in the past five years, with a fresh emphasis on first in class in its revamped pipeline, and how Biogen (NASDAQ:BIIB) could acquire its way into being a near-term growth company.

BioCentury’s editors also discuss the Biden administration’s initiative that seeks to compensate for decades of underinvestment in the nation’s biomanufacturing capacity and takeaways from Nora Volkow, director of NIH’s National Institute on Drug Abuse, during her appearance last week on The BioCentury Show.  

For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.